ScinoPharm Taiwan, Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 08, 2022 at 10:13 pm
Share
ScinoPharm Taiwan, Ltd. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was TWD 704.72 million compared to TWD 654.23 million a year ago. Net income was TWD 60.56 million compared to TWD 8.83 million a year ago. Basic earnings per share from continuing operations was TWD 0.08 compared to TWD 0.01 a year ago. Diluted earnings per share from continuing operations was TWD 0.08 compared to TWD 0.01 a year ago.
For the nine months, sales was TWD 2,248.19 million compared to TWD 2,043 million a year ago. Net income was TWD 251.64 million compared to TWD 189.77 million a year ago. Basic earnings per share from continuing operations was TWD 0.32 compared to TWD 0.24 a year ago. Diluted earnings per share from continuing operations was TWD 0.32 compared to TWD 0.24 a year ago.
ScinoPharm Taiwan Ltd is a Taiwan-based company mainly engaged in the research, development, manufacture and sale of active pharmaceutical ingredients. The main products include active pharmaceutical ingredients, protein drugs, oligonucleotides, peptides, injection preparations, new small molecule drugs and other chemical raw materials. The Company is also engaged in the provision of consulting and biotechnology services for related products, the international trading of products, as well as the provision of customized full-process services such as chemical molecular component synthesis, process development and commercial mass production. The Company operates within the domestic market and to overseas markets, including the Americas, Europe, Australia and Asia.
SCINOPHARM TAIWAN, LTD. 
